- Previous Close
5.94 - Open
6.18 - Bid 5.90 x 100
- Ask 6.12 x 100
- Day's Range
5.70 - 6.18 - 52 Week Range
5.40 - 20.83 - Volume
76,058 - Avg. Volume
201,318 - Market Cap (intraday)
35.212M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-11.41 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
www.atarabio.comRecent News: ATRA
View MorePerformance Overview: ATRA
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATRA
View MoreValuation Measures
Market Cap
35.21M
Enterprise Value
36.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.35
Price/Book (mrq)
--
Enterprise Value/Revenue
0.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-66.23%
Return on Assets (ttm)
-35.66%
Return on Equity (ttm)
--
Revenue (ttm)
128.94M
Net Income Avi to Common (ttm)
-85.4M
Diluted EPS (ttm)
-11.41
Balance Sheet and Cash Flow
Total Cash (mrq)
42.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.68M